A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06055894 |
Recruitment Status :
Recruiting
First Posted : September 28, 2023
Last Update Posted : March 22, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Myeloma, Smoldering | Dietary Supplement: Omega-3 Dietary Supplement: Curcumin Dietary Supplement: Probiotic Other: Whole food, plant-based diet (WFPBD) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | This is a randomized, non blinded, telehealth based, national pilot study with 100 patients (25 per arm). Randomization will be stratified based on BMI (normal/elevated) and Mayo risk SMM criteria. |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Microbial Changes in Response to a Plant Based Diet and/or Supplements in SMM Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via HealthTree |
Actual Study Start Date : | September 20, 2023 |
Estimated Primary Completion Date : | September 2026 |
Estimated Study Completion Date : | September 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Omega-3
For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily Qwell™ Omega 3 by The Veggie Doctor™. Each 820 mg omega 3 supplement capsule contains 700 mg Docosohexaenoic acid, 100 mg Docosapentaenoic acid, and 20 mg Eicosapentaenoic acid. No dietary changes will be made but data on dietary intake will be collected.
|
Dietary Supplement: Omega-3
For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily |
Experimental: Curcumin
For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily from Sabinsa pharmaceuticals. No dietary changes will be made but data on dietary intake will be collected.
|
Dietary Supplement: Curcumin
For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily |
Experimental: Probiotic
For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily from Vita Miracle pharmaceuticals. No dietary changes will be made but data on dietary intake will be collected.
|
Dietary Supplement: Probiotic
For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily |
Experimental: Whole food, plant-based diet (WFPBD)
For 2 weeks, on the WFPBD arm, patients will receive 14 items weekly, prepared and shipped by U.S. based company, Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2). The meals will contain legumes, fruits, vegetables, whole grains, and plant-based fats that have undergone minimal processing. Detailed recommendations for additional meals outside those given by Daily Harvet meeting the standard of a WFPBD will also be given to supplement their individual daily calorie needs through the guidance of the research dietitian. Patients will receive a varied menu created by Daily Harvest and the study team on a weekly basis.
|
Other: Whole food, plant-based diet (WFPBD)
Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2). |
- evaluate the change in Butyrate levels [ Time Frame: at 2 weeks ]To evaluate the change in stool butyrate levels, which is defined as the average of -1 and 0 week samples. Patient stool will be assessed for butyrate levels in batches by gas chromatography mass spectrometry.
- evaluate the change in Butyrate levels [ Time Frame: at 1 week ]To evaluate the change in stool butyrate levels which is defined as the average of -1 and 0 week samples. Patient stool will be assessed for butyrate levels in batches by gas chromatography mass spectrometry.
- Adherence [ Time Frame: at 2 weeks ]To evaluate the dietary or supplement compliance at 2 weeks. ≥ 70% of meals or pills during the 2-week intervention period, by ASA dietary recalls at each visit and pill diaries.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Confirmed prior diagnosis of smoldering myeloma (anytime prior). However, confirmation of SMM diagnosis must be documented in their last local oncologist clinic note within 6 months prior to study enrollment.
- Age ≥18 years
- Willingness to comply with all study-related procedures
- Physically able to complete requirements for the study or has someone to assist with the requirements (such as meal preparation, stool shipment and survey completion)
- Interested in learning to cook plant based recipes
- Access to smart mobile phone or device with camera and ability to download Keenoa app
- Be residing within the United States for the study duration.
- English speaking or a family member or caregiver who speaks English and is able to assist with the surveys and phone based Keenoa app.
Exclusion Criteria:
- Taking any supplements other than vitamin D, iron, vitamin B12, potassium, magnesium, calcium or those needed for a medical indication must be reviewed by PI. If patient is on a supplement (including curcumin, probiotic, omega3) they must stop these for 2 weeks prior to enrollment on study.
- Patients that already follow a whole foods plant based diet (ovo-lactovegetarian or processed junk food vegan diets are not excluded). This will be per research dietitian evaluation and discretion after nutrition screening.
- Legume allergy
- Severe allergies such as anaphylactic shock to peanuts and/or tree nuts, such as cashews
- Concurrent participation in weight loss/dietary trials or defined programs (that require specified diets/supplements on the program)
- Concurrent use of prescription weight loss (such as semaglutides and tirzepatides) and/or therapeutic myeloma drugs such as daratumumab, lenalidomide, etc.) within 12 weeks of consent
- Mental impairment leading to inability to cooperate
- Enrollment onto any other therapeutic investigational study
- Concurrent pregnancy
- Patients on full dose anticoagulation
- ≥ Grade 2 electrolyte (sodium and potassium) abnormalities as defined by CTCAEv5.0 (need to be resolved before enrolling on study)
- If in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely
- Current self reported heavy alcohol use (defined as >2 drinks per day or >14 drinks per week)
- Current self-reported illicit drug use (except inhaled marijuana, vaping or cigarette smoking. Oral marijuana/THC excluded or must stop >2 weeks prior.)
- Has a condition requiring antibiotics within 14 days of study intervention administration.
- Plan for travel during the study that would preclude adherence to prescribed diets
- History of active inflammatory bowel disease or major gastrointestinal surgery (not including appendectomy or cholecystectomy) within 3 months of enrollment or any history of total colectomy, or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e. restrictive procedures such as banding, are permitted)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06055894
Contact: Urvi Shah, MD | 646-608-3713 | shahu@mskcc.org | |
Contact: Alexander Lesokhin, MD | 646-608-3717 |
United States, New Jersey | |
Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Recruiting |
Basking Ridge, New Jersey, United States, 07920 | |
Contact: Urvi Shah, MD 646-608-3713 | |
Memorial Sloan Kettering Monmouth (All Protocol Activities) | Recruiting |
Middletown, New Jersey, United States, 07748 | |
Contact: Urvi Shah, MD 646-608-3713 | |
Memorial Sloan Kettering Bergen (All Protocol Activities) | Recruiting |
Montvale, New Jersey, United States, 07645 | |
Contact: Urvi Shah, MD 646-608-3713 | |
United States, New York | |
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) | Recruiting |
Commack, New York, United States, 11725 | |
Contact: Urvi Shah, MD 646-608-3713 | |
Memorial Sloan Kettering Westchester (All Protocol Activities) | Recruiting |
Harrison, New York, United States, 10604 | |
Contact: Urvi Shah, MD 646-608-3713 | |
Memorial Sloan Kettering Cancer Center (All Protocol Activities) | Recruiting |
New York, New York, United States, 10065 | |
Contact: Urvi Shah, MD 646-608-3713 | |
Memorial Sloan Kettering Nassau (All Protocol Activities) | Recruiting |
Uniondale, New York, United States, 11553 | |
Contact: Urvi Shah, MD 646-608-3713 |
Principal Investigator: | Urvi Shah, MD | Memorial Sloan Kettering Cancer Center |
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT06055894 |
Other Study ID Numbers: |
23-116 |
First Posted: | September 28, 2023 Key Record Dates |
Last Update Posted: | March 22, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Plant-Based Diet Dietary Supplements 23-116 |
Multiple Myeloma Neoplasms, Plasma Cell Smoldering Multiple Myeloma Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases |
Precancerous Conditions Hypergammaglobulinemia Curcumin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |